Repligen Corporation (RGEN)
RGEN Stock Price Chart
Explore Repligen Corporation interactive price chart. Choose custom timeframes to analyze RGEN price movements and trends.
RGEN Company Profile
Discover essential business fundamentals and corporate details for Repligen Corporation (RGEN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
29 Apr 1986
Employees
1.78k
Website
https://www.repligen.comCEO
Olivier Loeillot
Description
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
RGEN Financial Timeline
Browse a chronological timeline of Repligen Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Jul 2026
EPS estimate is $0.46, while revenue estimate is $201.40m.
Earnings released on 5 May 2026
EPS came in at $0.48 surpassing the estimated $0.38 by +26.32%, while revenue for the quarter reached $194.26m , beating expectations by +1.15%.
Earnings released on 24 Feb 2026
EPS came in at $0.49 surpassing the estimated $0.44 by +11.36%, while revenue for the quarter reached $197.91m , beating expectations by +2.58%.
Earnings released on 28 Oct 2025
EPS came in at $0.46 surpassing the estimated $0.42 by +9.52%, while revenue for the quarter reached $188.81m , beating expectations by +3.67%.
Earnings released on 29 Jul 2025
EPS came in at $0.37 falling short of the estimated $0.40 by -7.50%, while revenue for the quarter reached $182.37m , beating expectations by +4.10%.
Earnings released on 29 Apr 2025
EPS came in at $0.39 surpassing the estimated $0.35 by +11.43%, while revenue for the quarter reached $169.17m , beating expectations by +3.35%.
Earnings released on 20 Feb 2025
EPS came in at $0.44 surpassing the estimated $0.41 by +7.32%, while revenue for the quarter reached $167.55m , missing expectations by -0.06%.
Earnings released on 12 Nov 2024
EPS came in at $0.43 surpassing the estimated $0.34 by +28.21%, while revenue for the quarter reached $154.87m , beating expectations by +1.21%.
Earnings released on 30 Jul 2024
EPS came in at $0.33 matching the estimated $0.33, while revenue for the quarter reached $154.07m , missing expectations by -0.03%.
Earnings released on 1 May 2024
EPS came in at $0.28 falling short of the estimated $0.29 by -3.45%, while revenue for the quarter reached $151.35m , beating expectations by +0.86%.
Earnings released on 21 Feb 2024
EPS came in at $0.33 falling short of the estimated $0.34 by -2.94%, while revenue for the quarter reached $155.74m , beating expectations by +0.23%.
Earnings released on 31 Oct 2023
EPS came in at $0.23 surpassing the estimated $0.14 by +64.29%, while revenue for the quarter reached $141.19m , beating expectations by +0.36%.
Earnings released on 2 Aug 2023
EPS came in at $0.53 surpassing the estimated $0.49 by +8.16%, while revenue for the quarter reached $159.20m , missing expectations by -4.06%.
Earnings released on 2 May 2023
EPS came in at $0.64 surpassing the estimated $0.59 by +8.47%, while revenue for the quarter reached $182.66m , beating expectations by +0.68%.
Earnings released on 22 Feb 2023
EPS came in at $0.68 surpassing the estimated $0.58 by +17.24%, while revenue for the quarter reached $186.76m , beating expectations by +1.20%.
Earnings released on 1 Nov 2022
EPS came in at $0.77 surpassing the estimated $0.68 by +13.24%, while revenue for the quarter reached $200.74m , beating expectations by +4.83%.
Earnings released on 2 Aug 2022
EPS came in at $0.91 surpassing the estimated $0.72 by +26.39%, while revenue for the quarter reached $207.63m , beating expectations by +9.82%.
Earnings released on 27 Apr 2022
EPS came in at $0.92 surpassing the estimated $0.72 by +27.78%, while revenue for the quarter reached $206.40m , beating expectations by +11.28%.
Earnings released on 17 Feb 2022
EPS came in at $0.81 surpassing the estimated $0.65 by +24.62%, while revenue for the quarter reached $186.52m , beating expectations by +4.05%.
Earnings released on 28 Oct 2021
EPS came in at $0.78 surpassing the estimated $0.64 by +21.88%, while revenue for the quarter reached $178.22m , beating expectations by +8.69%.
Earnings released on 27 Jul 2021
EPS came in at $0.79 surpassing the estimated $0.53 by +49.06%, while revenue for the quarter reached $162.96m , missing expectations by -0.62%.
RGEN Stock Performance
Access detailed RGEN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
